Navigation Links
Aspirin reduces cardiovascular risks in men and women -- but differently

cardiovascular events could be prevented if aspirin was more widely used, Berger said

In his analysis, Berger combined the data from six different randomized clinical trials, which yielded a total of 95,456 patients, none of whom had coronary artery disease. Of that total, 51,342 were women. The trials all involved the comparison of low-dose aspirin versus placebo for the primary prevention of cardiovascular disease.

The analysis revealed that aspirin conferred a 12 percent reduction in risk in cardiovascular events for women, and a 14 percent reduction for men.

"Our findings are particularly noteworthy in that aspirin's main beneficial effects appeared to be the reduction in the risk of stroke for women and reduction in the risk of heart attacks for men," Berger said. "While our analysis showed that aspirin may have different effects in men and women, the relatively small number of heart attacks among women and strokes among men suggest that more research is needed to better understand any differences in cardiovascular responses to aspirin."

Specifically, among the 51,342 women in the analysis, there were 625 strokes and 469 heart attacks. Among the 44,114 men, there were 597 strokes and 1,023 heart attacks.

However, the routine use of aspirin does not come without potential risks, especially in terms of major bleeding episodes. The analysis found that routine aspirin use for an average of 6.4 years would lead to 2.5 major bleeding events per 1,000 women and 3 major bleeding events per 1,000 men.

"For this reason, while we believe that many more people could benefit from taking aspirin, it is important for patients and their physicians to discuss the issue and weigh the benefits and potential drawbacks to this therapy," Berger said. "Also, aspirin should never replace other ways of reducing cardiovascular risks, such eating a proper diet and exercising."

Of the six randomized clinical trials involved in the a
'"/>

Source:Duke University Medical Center


Page: 1 2 3

Related biology news :

1. Aspirin discovery may improve cancer treatments
2. Male circumcision reduces risk of HIV transmission from women to men
3. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
4. New miniaturised chip dramatically reduces time taken for DNA analysis
5. New processing method reduces peanut allergenicity
6. Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke
7. Study finds that nutritionally enhanced rice reduces iron deficiency
8. Overfishing in inland waters reduces biodiversity and threatens health
9. New gene reduces retinal degeneration in fruit flies
10. Prenatal nicotine exposure reduces breathing response of newborns...
11. Heat-shock protein vaccine reduces alveolar bone loss
Post Your Comments:
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... to their offering. One major ... technology. With continuous advances in technology, it is ... standard that meets the needs and expectations of ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... one of the most common and distressing symptoms cancer ... difficult for health care professionals to accurately assess its ... at Chicago are studying fatigue in cancer patients undergoing ... monitor behaviors such as smoking cessation and alcohol use. ...
... companies aren't touting that slogan. At least not yet. , ... Michigan State University professor of chemical engineering and materials science, ... more efficient and cost-effective. , Dale is internationally known ... plant biomass ?the stems, leaves, stalks and trunks of plants ...
... test a revolutionary treatment for blindness in children has ... The trial, funded by the Department of Health, is ... significant impact on future treatments for eye disease. ... have a condition called Leber’s congenital amaurosis (LCA), which ...
Cached Biology News:Cancer patients monitor fatigue in real time 2First clinical trial of gene therapy for childhood blindness 2
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... 21 Cardinal Health, a,global provider of products and ... today announced an order by the New York,Department of ... of,an expanding statewide plan to maintain emergency response readiness, ... Cardinal,Health over the past two years., Cardinal Health ...
... Feb. 21 Human Genome,Sciences, Inc. (Nasdaq: HGSI ... Executive Officer of Trevena, Inc., a privately held,drug discovery ... Directors.,Prior to joining Trevena, Dr. Gowen spent 15 years ... management positions in drug,discovery and development, and led the ...
... Inc.,(Nasdaq: MEDX ) is scheduled to announce ... February 26, 2008 by press release after the,financial ... will host a conference call,and live webcast at ... live, please,dial 1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and,enter ...
Cached Biology Technology:New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 3Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 4Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008 2
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Phospho-PERK (Thr980) Antibody...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: